Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir

Hepatology

Volumn 61, Issue 1, 2015, Pages 56-65

  Donaldson, Eric F ^a   Harrington, Patrick R ^a   O'Rear, Julian J ^a   Naeger, Lisa K ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; NONSTRUCTURAL PROTEIN 5B; SOFOSBUVIR; 2-((5-(2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YLMETHOXY)PHENOXYPHOSPHORYLAMINO)PROPIONIC ACID ISOPROPYL ESTER; NS-5 PROTEIN, HEPATITIS C VIRUS; URIDINE PHOSPHATE; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; BIOINFORMATICS; DNA POLYMORPHISM; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG TREATMENT FAILURE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1A; HEPATITIS C VIRUS GENOTYPE 1B; HUMAN; LIVER TRANSPLANTATION; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STRUCTURE; RELAPSE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BIOLOGY; ENZYMOLOGY; FOOD AND DRUG ADMINISTRATION; GENETICS; HEPACIVIRUS; METABOLISM; PHASE 3 CLINICAL TRIAL (TOPIC); SEQUENCE ANALYSIS; UNITED STATES;

AMINO ACID SUBSTITUTION; CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; SEQUENCE ANALYSIS, RNA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; URIDINE MONOPHOSPHATE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84920945807     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27375     Document Type: Article

References (16)

1. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-1877.
2. Lawitz EJ, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
3. Nyanguile O, Devogelaere B, Vijgen L, Van den Broeck W, Pauwels F, Cummings MD, et al. 1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus. J Virol 2010;84:2923-2934.
4. Mosley RT, Edwards TE, Murakami E, Lam AM, Grice RL, Du J, et al. Structure of hepatitis C virus polymerase in complex with primer-template RNA. J Virol 2012;86:6503-6511.
5. PyroMap. Available at: http://seqanswers.com/wiki/PyroMap.
6. Svarovskaia ES, Dvory-Sobol H, Hebner C, Doehle B, Gontcharova V, Martin R, et al. No resistance detected in four phase 3 clinical studies in HCV genotype 1-6 of sofosbuvir+ribavirin with or without peginterferon. 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, November 1-5, 2013.
7. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012;56:3359-3368.
8. Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis 2014;209:668-675.
9. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Zennou V, Otto MJ, et al. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA. J Virol 2011;85:12334-12342.
10. Fonseca NA, Rung J, Brazma A, Marioni JC. Tools for mapping high-throughput sequencing data. Bioinformatics 2012;28:3169-3177.
11. Lin PF, Samanta H, Rose RE, Patick AK, Trimble J, Bechtold CM, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994;170:1157-1164.
12. Larder BA, Chesebro B, Richman DD. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother 1990;34:436-441.
13. Komatsu TE, Pikis A, Naeger LK, Harrington PR. Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways. Antiviral Res 2014;101:12-25.
14. Sun JH, O'Boyle DR, Zhang Y, Wang C, Nower P, Valera L, et al. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology 2012;55:1692-1699.
15. Verbinnen T, Jacobs T, Vijgen L, Ceulemans H, Neyts J, Fanning G, et al. Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays. J Antimicrob Chemother 2012;67:2327-2337.
16. Hang JQ, Yang Y, Harris SF, Leveque V, Whittington HJ, Rajyaguru S, et al. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus. J Biol Chem 2009;284:15517-15529.